Systematic review of efficacies and adverse effects of treatments for Pityriasis lichenoides by Jung, F. et al.
 
 
Title/short title:  
Systematic Review of Efficacies and Adverse Effects of Treatments for Pityriasis Lichenoides 
F. Jung1, C. Sibbald1, M. Bohdanowicz1, J. R. Ingram2, V. Piguet1,2,3 
 
1Division of Dermatology, Department of Medicine, University of Toronto School of Medicine, Toronto, Ontario, 
Canada. 
2Dermatology, Division of Infection & Immunity, Cardiff University, Wales, UK  








Flora Jung BMSc, MD(c) 
Faculty of Medicine, University of Toronto  
1 King’s College Circle 
Toronto, Ontario M5S 3K1, Canada 
(519) 496-0668 
Email: flora.jung@mail.utoronto.ca  
  
Vincent Piguet MD, PhD, FRCP 
Division of Dermatology, Department of Medicine, University of Toronto  
Division of  Dermatology, Women’s College Hospital, 76 Grenville St, Office 6425 
Toronto, Ontario M5S 1B2, Canada 
(416) 323-6400 x5825 
Email: vincent.piguet@utoronto.ca  
 
Funding statement: None 
Disclosures: Dr. J. R. Ingram is Editor of the British Journal of Dermatology. The remaining 




What’s already known about this topic?  
• Pityriasis lichenoides (PL) is a spectrum of dermatoses characterized by 
papulosquamous lesions.  
• There is no current consensus on the treatment of PL and no previous systematic 
reviews have assessed this. 
What does this study add?  
• Most studies for treatment of PL are hospital-based and few randomized controlled 
studies exist. 
• We highlight the importance of distinguishing between PLC and PLEVA patients in 
assessing treatment outcomes, extending the length of follow-up for PLC patients in 
remission, and propose a standardized definition of PL complete and partial remission. 
















Introduction: Pityriasis lichenoides (PL) is a papulosquamous dermatosis affecting both children 
and adults for which no standard treatment currently exists. The aims of our systematic review 
were to characterize different treatment options and develop an evidence-based treatment 
algorithm for PL.  
 
Methods: A systematic search of published literature on PL treatments was performed on 
December 23rd, 2017 via the Medline, Embase, CINAHL, CENTRAL, ClinicalTrials.gov, and the EU 
Clinical Trials Register databases.  
 
Results: Of 1090 abstracts retrieved, 27 full-text articles with 502 participants were included for 
analysis. 17 of the full-text articles were retrospective cohorts and 2 were randomized control 
studies. Treatment modalities included in these articles were phototherapy, antibiotics, 
methotrexate, pyrimethamine and trisulfapyrimidine, corticosteroids (CTS) and conservative 
treatment. Of these treatments, phototherapy led to complete remission in the highest 
proportion of patients and topical CTS was found to have been trialed in the highest number of 
patients.  
 
Conclusions: The current literature consists almost entirely of uncontrolled studies and none 
provide compelling data to support an evidence-based approach to PL treatment. PLC and 
PLEVA should be distinguished in response to treatment and definitions of response to 
treatment must be standardized. Additional randomized control studies with longer follow-ups 








Pityriasis lichenoides (PL) is a papulosquamous dermatosis of unknown etiology affecting both 
children and adults1. It is thought to encompass a spectrum including both acute and chronic 
forms, pityriasis lichenoides et varioliformis acuta (PLEVA), and pityriasis lichenoides chronica 
(PLC)2,3.  PLEVA, also known by its eponym Mucha-Haberman disease (MHD), is the self-limited 
acute form typified by generalized papules that undergo necrosis and varioliform scarring4. The 
chronic form, PLC, is characterized by red scaly macules that periodically relapse and undergo 
remission over several years3,5. PLC and PLEVA lesions tend to show predilection for the 
anterior trunk, flexural surfaces, and proximal extremities, and the two may co-exist in the 
same patient5. While the disease is often benign, systemic symptoms such as fever and 
lymphadenopathy have been known to occur, especially in the acute presentation4,6. 
 
PL is not uncommon with an incidence estimated at 0.05%1. It appears to have no racial or 
geographic predisposition, although it is seen slightly more in males in late childhood or young 
adulthood2,7,8. Diagnosis of this disease is made through clinical presentation and skin biopsy. 
Histopathologically, PL often demonstrates parakeratosis, spongiosis and extravasation of 
lymphocytes with epidermal invasion3,9.  
 
Cosmetic and symptomatic concerns of PL patients have led to the development of treatment 
options despite its benign course. Ultraviolet therapy, anti-bacterials such as erythromycin and 
tetracycline, and immunosuppressants such as methotrexate are among the major therapies 
that have been explored8,10–15. However, with each having different success rates and adverse 
effect profiles, no standard treatment modality currently exists for PL. The aims of the analysis 
were to characterize different treatment options and develop an evidence-based treatment 
algorithm for PL.    
 
Methods 
The protocol for this review was defined a priori and registered online in the PROSPERO 




A literature search was performed of the following databases for studies up to December 23rd, 
2017: MEDLINE via Ovid; EMBASE via Embase.com; the Cochrane Skin Group Specialised 
Register and the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane 
Library; the Cumulative Index to Nursing and Allied Health Literature (CINAHL); ClinicalTrials.gov; 
and the European Union (EU) Clinical Trials Register. The search was limited to published 
English-language papers and human subjects. Search strings were developed for each database, 
including keywords and subject headings for PL (Appendix S1). All abstracts were reviewed by 
two authors, with conflicts resolved by a third, to select relevant articles. Data extraction was 
performed by two authors with 20% overlap and no significant discrepancies were identified. 
 
Types of studies 
Inclusion criteria were cohort, case-control, randomized-control, cross-sectional and case series 
studies. Exclusion criteria were reviews, ongoing studies, conference proceedings and abstracts 
and case series where n<5.  
 
Types of participants 
Inclusion criteria were participants of any age, ethnicity or genders with PLC or PLEVA. To 
maximize cases identified, there were no exclusion criteria. 
 
Primary outcome measures 
Primary outcome measures were characteristics of treatment regimens for PLC and PLEVA, 
characterized by their doses, durations and patient selection descriptors. In addition, we 
studied the clinical effects of those treatment regimens, characterized by their rates of success 
in eliciting partial and complete remission and their association with any adverse effects.  
 
Secondary outcome measures 
Secondary outcomes measures included the time frame for response of each treatment for PLC 
and PLEVA, and any data on recurrence.  
 
Risk of bias 
Risk of bias assessments were completed by two independent reviewers (F.J., C.S, Appendix S2). 
The Newcastle-Ottawa Scale was used to assess risk of bias for cohort studies16. The Cochrane 
Risk of Bias Assessment Tool was used to assess randomized control trials17. Disagreements 
were resolved by consensus and discussion.  
 
Results 
The search strategy results are summarized in Figure 1. Of 1090 abstracts retrieved, 929 studies 
were excluded in title and abstract screening. Of the 159 studies included in the full-text 
screening, 27 full-text articles with a combined total of 502 patients were included for analysis: 
16 retrospective cohort studies, 7 prospective cohort studies, 2 randomized control studies, 
and 2 case series. One article was excluded after two independent raters failed to retrieve it 
despite best efforts; based on the title which describes assessing phototherapy for all pediatric 
patients, it is unlikely to have included many PL patients.  
 
Between the two controlled trials published to date, both had a limited sample and one 
compared UVB only against PUVA22,31. Of the 17 studies that reported the population source of 
their subjects, 13 studies reported on patients treated at an institution or hospital; the 
remaining studies included patients treated either by an individual practitioner or a regional 
community clinic.  Table 1 includes the patient demographics, interventions and treatment 
responses reported by individual studies. Definitions of complete and partial remission used by 
each study, where available, have also been reported in Table 1.  
 














Phototherapy (including BB-UVB, NB-UVB and UVA) was given to 309 subjects14,15,26–35,18–25. One 
study (n=15) utilized heliotherapy27. BB-UVB, NB-UVB and UVA modalities were either used in 
isolation, in combination with one another, or in combination with other topical or systemic 
interventions. The most common frequency of treatment for UV therapy was 3 times weekly. In 
7 subjects, phototherapy or combinatory phototherapy was listed as a previous treatment with  
partial or poor effect18,36,37. One study not included in this sum reported that 6 of their subjects 
were previously treated with NB-UVB, antibiotics and/or systemic steroids36.  
 
Complete response using UVB, BB-UVB, NB-UVB, and PUVA in isolation with or without topical 
emollients was reported in 53.2% (n=25/47), 90.9% (n=20/22), 75.0% (n=102/136) and 69.4% 
(n=25/36) subjects, respectively. Partial response was reported in 31.9% (n=15/47), 0% 
(n=0/22), 20.6% (n=28/136) and 22.2% (n=8/36) subjects, respectively. In one of these studies, 
2 subjects experienced complete remission (CR) and 1 subject experienced partial remission (PR) 
after being treated with NB-UVB following an unsuccessful intervention with antibiotics32.  
 
Of the studies which assessed or reported relapse rates after phototherapy in isolation or with 
other therapies, 66 subjects experienced relapse of either PLC or PLEVA18,21–24,28–30,33,37.  
 
Reported side effects for phototherapy include erythema (n=32), pruritus (n=5, burning (n=1), 
tingling (n=1), folliculitis (n=1), headaches (n=1) and dryness (n=8)15,18,19,21,25,28,29,31,33,37. The 
most common adverse effect, erythema, ranged from “mild” to “severe”; in one study, it was 
reported to be severe enough in 5 subjects to warrant discontinuation of phototherapy15. 
 
For the 15 subjects treated annually with heliotherapy at a frequency of 10 days per year, 60% 
had all or almost all lesions cleared for at least two years after treatment and 27% had at least 
50% of lesions cleared for at least two years after treatment27. No adverse effects were 
described. 
Antibiotics 
One hundred and twenty-four subjects were treated with erythromycin, tetracycline, 
doxycycline or another antibiotic30–35,38–40. In 40 subjects, antibiotics were listed as a previous 
treatment but the effect and the name of the antibiotic was rarely 
documented14,15,18,21,22,24,29,30,32,36. In one study, 4 of 7 subjects who received antibiotic 
treatment exhibited no response; these 4 subjects were then treated with NB-UVB, and 3 
responded at least partially32.  In two of the studies not included in this sum, one reported that 
6 of their subjects were previously treated with NB-UVB, antibiotics and/or systemic steroids 
while the other reported “most” of their 11 subjects were previously treated with topical 
corticosteroids (CTS) and systemic tetracycline15,36.  
 
Complete response using erythromycin or tetracycline in isolation was reported in 66.0% 
(n=31/47) and 52.9% (n=9/17) subjects, respectively. Partial response was reported in 8.5% 
(n=4/47) and 35.3% (n=6/17) subjects, respectively. Of the studies which reported a rate, 16 
subjects experienced relapse of either PLC or PLEVA after treatment antibiotics in isolation or in 
combination with another intervention30,33,38–40.  
 
Adverse effects were only reported by one study where subjects were treated with 20-50mg/kg 
of erythromycin daily in 2-4 divided doses over four months38; pruritus and arthralgia was 
reported in 79% and 4%, respectively, of the 24 subjects who participated in the study.  
 
Methotrexate 
Methotrexate was used to treat 6 MHD subjects of 1 case series at individualized doses and 
frequencies for each of the subjects; the method used to calculate these dosing patterns were 
not described12. The study did not provide a definition for CR, but reported CR was observed in 
all 6 subjects. All 6 subjects experienced remission after an undefined period of monitoring. No 




Bromelain, a proteolytic enzyme derived from the stem of a pineapple plant, was used to treat 
subjects with PLC in 1 prospective cohort study (n=8)36. CR was defined by the study as 100% of 
lesions cleared and CR was reported in all 8 subjects. Relapse was observed in 25% of subjects 
(n=2) within 1 year. No adverse effects were described. 
 
Pyrimethamine and trisulfapyrimidine 
Among the different hypotheses proposed for the etiology of PLC, infectious agents have been 
postulated. One study used a treatment regimen of two antiparasitic drugs, pyrimethamine and 
trisulfapyrimidine to assess if the common parasite toxoplasma gondii has a role in PLC41. Eight 
of the 22 subjects in this study were found to be Toxoplasma seropositive and all five patients 
who experienced complete subsidence of skin lesions were Toxoplasma seropositive. No 
relapse rates or adverse effects were reported in these five patients. The remaining 17 subjects 
exhibited no response to pyrimethamine and trisulfapyrimidine. 
 
Corticosteroids 
One hundred and one subjects were treated with CTS in isolation or in combination with 
another therapy14,30–33,35. Complete response using CTS in isolation was reported in 4.4% 
(n=2/45)31. Partial response was reported in 80.0% (n=20/25) subjects30,31. CTS were the most 
commonly reported treatment previously used among all of the subjects assessed in this review. 
63 reported subjects, and substantially more unreported subjects, received either topical or 
oral steroids as a previous treatment12,14,35,40,15,18,21,22,24,25,29,30. CTS effect was often unreported 
or reported to be unsuccessful; one study stated that it was “effective” for only 2 out of “most” 
of their 157 subjects who had received CTS treatment30.  
 
No study reported adverse effects of CTS. No relapse rates were reported in studies where CTS 
were used in isolation as an intervention, and the isolated effects of CTS are difficult to 
determine in the setting of studies which utilized combinatory therapies. 
 
Conservative treatment 
Two subjects received no active treatment and were observed only32,35. Further data is only 
available for one of the two subjects who experienced complete resolution of lesions32. No 
relapse rates were reported. 
 
Other treatments 
Topical emollients and anti-histamines have also been utilized in combination with other 
therapies, however their isolated effect on lesions, relapse rates and adverse effects, if any, are 
difficult to determine15,33. 
 
Risk of bias 
An assessment of risk of bias is included in Appendix A2. Both RCTs had low rates of incomplete 
data but high rates of bias (Appendix A2). Only two of 23 cohort studies had a comparable 
control population or a population controlled for age. Otherwise, the cohort studies each had a 
moderate level of risk of bias.  
 
Discussion 
This systematic review aimed to provide an updated review of the spectrum and efficacy of 
treatments in PLC and PLEVA. We build upon recent work by Bellinato et al. on PL treatments 
by summarizing the adverse effects and rates of relapse reported for individual treatments, in 
addition to identifying opportunities to improve gaps in current PL literature42. Our overall 
findings reveal underwhelming quality and quantity of evidence for PL treatments. The majority 
of studies retrieved had a small sample size (n≤15) and were hospital-based, limiting their 
generalizability, and none had robust evidence to support a specific treatment option for PL.  
 
Summary of current evidence available for the treatment of PL 
While no study provided any robust evidence, of the treatment options and combinations 
described for PL, phototherapy, antibiotics and corticosteroids has been studied the most; with 
CR being achieved in 53.2-90.9%, 52.9-66.0% and 4.4% of subjects treated by the respective 
interventions, and PR being achieved in 0-22.2%, 8.5-35.3% and 80.0%. Of these treatments, 
BB-UVB demonstrated the highest rate of success in achieving CR with a rate of 90.9%; however, 
only 22 subjects thus far have been trialed on BB-UVB, and further studies of its efficacy and 
side effects are necessary to elucidate its potential as an option for PL therapy. Of the adverse 
effects currently known to have been associated with phototherapy, the most common is 
erythema, which led to discontinuation of treatment in 46% of subjects (n=5) in 1 study15. Using 
the minimal erythema dose (MED) to calculate the initial dose may help minimize the risk of 
this side effect43.  
 
Only two randomized control trials were found22,31. In one study (n=30), PUVA had the highest 
rate of remission as compared to topical CTS or topical CTS with tetracycline31. Respectively, 
62.5% (n=5/8), 25% (n=2/8) and 7% (n=1/14) patients treated with these interventions 
experienced CR and 25% (n=2/8), 25% (n=2/8), and 79% (n=11/14) experienced PR. Significant 
therapeutic results were only observed with PUVA compared to tetracycline and/or CTS, and 
the researchers concluded that PUVA is more effective than the other tested modes of 
treatment for PL31. However, it should be noted that the clinical setting and geographical 
location from which subjects were recruited for this study is unknown, making these 
conclusions challenging to contextualize. In the other study, PUVA was compared with NB-UVB, 
but no significant difference was found between the two modalities22.  
 
Identified gaps and problems with current literature on PL treatments 
PLC and PLEVA patients should be distinguished in their response to treatment 
As PLC and PLEVA are both uncommon diseases but are both considered on the spectrum of PL, 
many studies to date have not distinguished between the two when reporting response to 
treatment, rates of remission, and rates of adverse effects. However, PLC and PLEVA are 
dissimilar in histopathology, morphology, and pattern of recurrence as described elsewhere2. It 
is highly likely that neglecting to distinguish between the two in the assessment of their 
response to treatments is inappropriate and may have implications to clinical safety. Studies 
which distinguish between PLC and PLEVA are highly recommended to improve the body of 
literature available for these distinct subsets of PL, and those that do not distinguish between 
the two are discouraged.  
 
Follow-up on rates of relapse following PL remission should extend 12 months 
The majority of studies to date either did not report any follow-up data or followed patients for 
less than one year. While this likely has less significant implications for the study of patients 
with PLEVA, PLC is a subset of PL which is chronic, and is a disease characterized by its potential 
to undergo remission for years before the patient relapses3,5. Although loss to follow-up in 
clinical trials is often a challenge, for studies assessing PLC patients, we recommend that 
completion of the trial is essential to assess true response to treatment. We recommend the 
length of follow-up for PLC patients following remission be extended to 12 months, as 
spontaneous regression of PL is reported to be seen on average between 3 to 12 months10.  
 
Heterogeneity in outcome definitions and outcome measures limit analysis 
A limitation of our analysis was the variation in outcome definitions between studies, with 
several studies defining CR as at least 90% of lesions cleared and PR as 50-90% of lesions 
cleared18,22,23, while another study defined CR as at least 75% of lesions cleared and PR as 50-75% 
of lesions cleared44. Similarly, the heterogeneity in outcome measures assessed between 
studies made pooling of results impossible, and contributed to lack of sufficient data on 
duration of follow-up, quality of life, relapse rates and adverse effects for all treatments. 
Overall, adverse effects, quality of life, and relapse rates of PL treatments have been 
underreported, with more than half of the studies not including this information.  
 
Impact of gaps in literature on clinical practice 
During the course of this review, we found that these gaps ultimately limited our capacity to 
address the primary aim of this study. The current literature on the efficacy, benefits, and risk 
of PL treatments is not conducive to a rigorous pooled comparison. The potential of ongoing PL 
research is impeded by this lack of a standard definition and methodology, and it propagates 
the problem for practitioners seeking an evidence-based algorithm to address the concerns of 
their PL patients. 
 
We advocate for changes which support the potential for such an evidence-based treatment 
algorithm for PL, and propose standardized definitions and standardized reporting of specific 
treatment outcomes. Based on the definitions used most frequently by studies to date, we 
recommend “complete remission” for future PL studies to be defined as no less than 90% of 
lesions cleared, and “partial remission” to be defined as no less than 50% of lesions cleared. We 
also recommend the following outcome measures be reported by each study: patient’s PL 
subtype, mean duration with PL, history of previous treatments, dose of treatment, response to 
treatment (complete, partial, or no response), time for response to treatment, length of follow-
up, rate of relapse, and adverse effects. 
 
Conclusions 
There is currently insufficient evidence to recommend an algorithmic approach for the 
treatment of PLC or PLEVA and a lack of understanding regarding the potential adverse effects 
of treatment to patients. While there is more evidence for phototherapy compared to other 
treatments, overall, more randomized control studies with standardized outcomes and longer 
follow-ups are required to truly understand the impact of medical intervention. Our 
recommendations for future studies are to distinguish between PLC and PLEVA patients in 
assessing treatment outcomes, to extend the length of follow-up of at least PLC patients, and to 
report based on the proposed definitions of complete and partial remission and outcome 
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